Marcum Wealth LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,363 shares of the company’s stock after purchasing an additional 1,100 shares during the quarter. Marcum Wealth LLC’s holdings in AstraZeneca were worth $634,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in the stock. Wellington Management Group LLP lifted its stake in shares of AstraZeneca by 0.7% during the 3rd quarter. Wellington Management Group LLP now owns 49,492,814 shares of the company’s stock worth $3,351,653,000 after purchasing an additional 358,399 shares during the last quarter. Capital International Investors raised its stake in AstraZeneca by 0.5% in the fourth quarter. Capital International Investors now owns 34,782,762 shares of the company’s stock valued at $2,342,367,000 after buying an additional 164,183 shares during the last quarter. Sanders Capital LLC raised its stake in shares of AstraZeneca by 39.0% in the fourth quarter. Sanders Capital LLC now owns 14,684,066 shares of the company’s stock worth $988,972,000 after purchasing an additional 4,122,965 shares during the last quarter. CIBC Private Wealth Group LLC raised its stake in shares of AstraZeneca by 9.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 10,424,914 shares of the company’s stock worth $708,617,000 after purchasing an additional 889,178 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of AstraZeneca by 2.5% in the fourth quarter. Fisher Asset Management LLC now owns 9,404,023 shares of the company’s stock worth $633,361,000 after purchasing an additional 233,015 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca Stock Up 0.4 %
Shares of AZN opened at $78.88 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $80.86. The stock’s 50 day moving average is $76.48 and its two-hundred day moving average is $69.82. The firm has a market cap of $244.57 billion, a P/E ratio of 38.67, a PEG ratio of 1.41 and a beta of 0.48.
Analyst Ratings Changes
Several research analysts have recently issued reports on the company. Argus raised their price objective on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. BMO Capital Markets raised their price objective on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, The Goldman Sachs Group began coverage on AstraZeneca in a report on Thursday, May 30th. They set a “buy” rating and a $97.00 target price on the stock. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of $88.00.
Read Our Latest Stock Report on AstraZeneca
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- 5 discounted opportunities for dividend growth investors
- McDonald’s Stock: Balancing Value and Innovation
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- MarketBeat Week in Review – 6/17 – 6/21
- The Role Economic Reports Play in a Successful Investment Strategy
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.